4.7 Review

Genomics of chronic allograft injury

期刊

KIDNEY INTERNATIONAL
卷 78, 期 -, 页码 S33-S37

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2010.420

关键词

Affymetrix; chronic rejection; GeneChip; kidney transplantation; microarray

资金

  1. Pfizer (Wyeth)
  2. Genentech
  3. Novartis
  4. Wyeth
  5. Roche
  6. Jansen Cilag
  7. Astellas
  8. NHMRC of Australia
  9. NIH
  10. JDRF

向作者/读者索取更多资源

Chronic allograft injury (CAI) is common after kidney transplantation in which immunological (e.g., acute and chronic cellular and antibody-mediated rejection) and nonimmunological factors (e.g., donor-related factors, ischemia-reperfusion injury, polyoma virus, hypertension, and calcineurin inhibitor nephrotoxicity) have a role. Despite the new Banff pathological classification, histopathological diagnosis is still far from being the 'gold standard' to understand the exact mechanisms in the development of CAI, which may lead to appropriate treatment. Microarray is a powerful technology that detects thousands of genes simultaneously and might be an important tool in elucidating patterns for mechanism, diagnosis, prognosis, and treatment of complex, multifactorial diseases, such as CAI. In this review, we discuss the studies that applied microarray technology in kidney transplant patients with CAI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据